Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALLY-MF: DISC-0974 in Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198Phase 2Recruiting
- Sponsor
- Disc Medicine
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of selcodebart in anemia (2 arms), sponsored by Disc Medicine. Primary endpoints: Safety and Tolerability of DISC-0974 at Day 169, Transfusion Independence in TD Cohorts at Day 169 and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
selcodebart
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05320198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320198.